Cargando…

Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma

Cutaneous T cell lymphoma (CTCL) is a spectrum of lymphoproliferative disorders caused by the infiltration of malignant T cells into the skin. The most common variants of CTCL include mycosis fungoides (MF), Sézary syndrome (SS) and CD30(+) Lymphoproliferative disorders (CD30(+) LPDs). CD30(+) LPDs...

Descripción completa

Detalles Bibliográficos
Autores principales: Gill, Raman Preet Kaur, Gantchev, Jennifer, Martínez Villarreal, Amelia, Ramchatesingh, Brandon, Netchiporouk, Elena, Akilov, Oleg E., Ødum, Niels, Gniadecki, Robert, Koralov, Sergei B., Litvinov, Ivan V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870189/
https://www.ncbi.nlm.nih.gov/pubmed/35203244
http://dx.doi.org/10.3390/cells11040593
_version_ 1784656678751305728
author Gill, Raman Preet Kaur
Gantchev, Jennifer
Martínez Villarreal, Amelia
Ramchatesingh, Brandon
Netchiporouk, Elena
Akilov, Oleg E.
Ødum, Niels
Gniadecki, Robert
Koralov, Sergei B.
Litvinov, Ivan V.
author_facet Gill, Raman Preet Kaur
Gantchev, Jennifer
Martínez Villarreal, Amelia
Ramchatesingh, Brandon
Netchiporouk, Elena
Akilov, Oleg E.
Ødum, Niels
Gniadecki, Robert
Koralov, Sergei B.
Litvinov, Ivan V.
author_sort Gill, Raman Preet Kaur
collection PubMed
description Cutaneous T cell lymphoma (CTCL) is a spectrum of lymphoproliferative disorders caused by the infiltration of malignant T cells into the skin. The most common variants of CTCL include mycosis fungoides (MF), Sézary syndrome (SS) and CD30(+) Lymphoproliferative disorders (CD30(+) LPDs). CD30(+) LPDs include primary cutaneous anaplastic large cell lymphoma (pcALCL), lymphomatoid papulosis (LyP) and borderline CD30(+) LPD. The frequency of MF, SS and CD30(+) LPDs is ~40–50%, <5% and ~10–25%, respectively. Despite recent advances, CTCL remains challenging to diagnose. The mechanism of CTCL carcinogenesis still remains to be fully elucidated. Hence, experiments in patient-derived cell lines and xenografts/genetically engineered mouse models (GEMMs) are critical to advance our understanding of disease pathogenesis. To enable this, understanding the intricacies and limitations of each individual model system is highly important. Presently, 11 immortalized patient-derived cell lines and different xenograft/GEMMs are being used to study the pathogenesis of CTCL and evaluate the therapeutic efficacy of various treatment modalities prior to clinical trials. Gene expression studies, and the karyotyping analyses of cell lines demonstrated that the molecular profile of SeAx, Sez4, SZ4, H9 and Hut78 is consistent with SS origin; MyLa and HH resemble the molecular profile of advanced MF, while Mac2A and PB2B represent CD30(+) LPDs. Molecular analysis of the other two frequently used Human T-Cell Lymphotropic Virus-1 (HTLV-1)(+) cell lines, MJ and Hut102, were found to have characteristics of Adult T-cell Leukemia/Lymphoma (ATLL). Studies in mouse models demonstrated that xenograft tumors could be grown using MyLa, HH, H9, Hut78, PB2B and SZ4 cells in NSG (NOD Scid gamma mouse) mice, while several additional experimental GEMMs were established to study the pathogenesis, effect of drugs and inflammatory cytokines in CTCL. The current review summarizes cell lines and xenograft/GEMMs used to study and understand the etiology and heterogeneity of CTCL.
format Online
Article
Text
id pubmed-8870189
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88701892022-02-25 Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma Gill, Raman Preet Kaur Gantchev, Jennifer Martínez Villarreal, Amelia Ramchatesingh, Brandon Netchiporouk, Elena Akilov, Oleg E. Ødum, Niels Gniadecki, Robert Koralov, Sergei B. Litvinov, Ivan V. Cells Review Cutaneous T cell lymphoma (CTCL) is a spectrum of lymphoproliferative disorders caused by the infiltration of malignant T cells into the skin. The most common variants of CTCL include mycosis fungoides (MF), Sézary syndrome (SS) and CD30(+) Lymphoproliferative disorders (CD30(+) LPDs). CD30(+) LPDs include primary cutaneous anaplastic large cell lymphoma (pcALCL), lymphomatoid papulosis (LyP) and borderline CD30(+) LPD. The frequency of MF, SS and CD30(+) LPDs is ~40–50%, <5% and ~10–25%, respectively. Despite recent advances, CTCL remains challenging to diagnose. The mechanism of CTCL carcinogenesis still remains to be fully elucidated. Hence, experiments in patient-derived cell lines and xenografts/genetically engineered mouse models (GEMMs) are critical to advance our understanding of disease pathogenesis. To enable this, understanding the intricacies and limitations of each individual model system is highly important. Presently, 11 immortalized patient-derived cell lines and different xenograft/GEMMs are being used to study the pathogenesis of CTCL and evaluate the therapeutic efficacy of various treatment modalities prior to clinical trials. Gene expression studies, and the karyotyping analyses of cell lines demonstrated that the molecular profile of SeAx, Sez4, SZ4, H9 and Hut78 is consistent with SS origin; MyLa and HH resemble the molecular profile of advanced MF, while Mac2A and PB2B represent CD30(+) LPDs. Molecular analysis of the other two frequently used Human T-Cell Lymphotropic Virus-1 (HTLV-1)(+) cell lines, MJ and Hut102, were found to have characteristics of Adult T-cell Leukemia/Lymphoma (ATLL). Studies in mouse models demonstrated that xenograft tumors could be grown using MyLa, HH, H9, Hut78, PB2B and SZ4 cells in NSG (NOD Scid gamma mouse) mice, while several additional experimental GEMMs were established to study the pathogenesis, effect of drugs and inflammatory cytokines in CTCL. The current review summarizes cell lines and xenograft/GEMMs used to study and understand the etiology and heterogeneity of CTCL. MDPI 2022-02-09 /pmc/articles/PMC8870189/ /pubmed/35203244 http://dx.doi.org/10.3390/cells11040593 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gill, Raman Preet Kaur
Gantchev, Jennifer
Martínez Villarreal, Amelia
Ramchatesingh, Brandon
Netchiporouk, Elena
Akilov, Oleg E.
Ødum, Niels
Gniadecki, Robert
Koralov, Sergei B.
Litvinov, Ivan V.
Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma
title Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma
title_full Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma
title_fullStr Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma
title_full_unstemmed Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma
title_short Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma
title_sort understanding cell lines, patient-derived xenograft and genetically engineered mouse models used to study cutaneous t-cell lymphoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870189/
https://www.ncbi.nlm.nih.gov/pubmed/35203244
http://dx.doi.org/10.3390/cells11040593
work_keys_str_mv AT gillramanpreetkaur understandingcelllinespatientderivedxenograftandgeneticallyengineeredmousemodelsusedtostudycutaneoustcelllymphoma
AT gantchevjennifer understandingcelllinespatientderivedxenograftandgeneticallyengineeredmousemodelsusedtostudycutaneoustcelllymphoma
AT martinezvillarrealamelia understandingcelllinespatientderivedxenograftandgeneticallyengineeredmousemodelsusedtostudycutaneoustcelllymphoma
AT ramchatesinghbrandon understandingcelllinespatientderivedxenograftandgeneticallyengineeredmousemodelsusedtostudycutaneoustcelllymphoma
AT netchiporoukelena understandingcelllinespatientderivedxenograftandgeneticallyengineeredmousemodelsusedtostudycutaneoustcelllymphoma
AT akilovolege understandingcelllinespatientderivedxenograftandgeneticallyengineeredmousemodelsusedtostudycutaneoustcelllymphoma
AT ødumniels understandingcelllinespatientderivedxenograftandgeneticallyengineeredmousemodelsusedtostudycutaneoustcelllymphoma
AT gniadeckirobert understandingcelllinespatientderivedxenograftandgeneticallyengineeredmousemodelsusedtostudycutaneoustcelllymphoma
AT koralovsergeib understandingcelllinespatientderivedxenograftandgeneticallyengineeredmousemodelsusedtostudycutaneoustcelllymphoma
AT litvinovivanv understandingcelllinespatientderivedxenograftandgeneticallyengineeredmousemodelsusedtostudycutaneoustcelllymphoma